2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1148 Genomic and functional analysis of a sickle cell disease individual with high levels of hematopoietic stem and progenitor cells in the peripheral blood

Neha H. Suresh, Alex Pendergast, BS2, Justin J Yoo, M.D.3, Mary C Aliche, BS4, Rachel Choi, BS5, Vivien A Sheehan, MD,PhD6
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
5 Emory University School of Medicine, Atlanta, Georgia, United States
6 Emory University School of Medicine, Atlanta, Georgia, United States

Introduction: Ex vivo gene therapy for sickle cell disease (SCD) requires sufficient functional CD34+ hematopoietic stem and progenitor cells (HSPCs). However, in SCD, safety limitations on certain exogenous mobilizing agents remain significant barriers. Prior GWAS and fine-mapping studies have identified regulatory loci associated with blood CD34+ cell levels, including CXCR4, PPM1H, and ENO1/RERE (de Lapuente Portilla et al., 2022; Ali et al., 2026). Typical yields of CD34+ cells from red cell exchange (RCE) bags are ~5 million cells with >95% purity. We identified an outlier donor SCD155 whose RCE bags yield ~70 million with >95% purity without drug mobilization. Here we describe our functional and genomics investigation. 

Methods: PBMCs were isolated from RCE; CD34+ cells were extracted by magnetic bead selection. CD34+ cell yield, flow-cytometry-assessed purity, and CD34+ cells/PBMCs (%) were summarized across collections and benchmarked against other SCD patient CD34+ isolations. CD34+ cells were evaluated functionally in vitro with a 2-phase erythroid differentiation culture; F-cell percentage was measured by flow cytometry, and %HbF  by HPLC. In vivo hematopoietic function and engraftment was assessed by transplanting four busulfan-conditioned NBSGW mice with 6.8 × 10⁵ SCD155 CD34+ cells each, retro-orbitally, with engraftment measured 16-18 weeks post-transplant by flow cytometry as %hCD45/(hCD45+mCD45). Engraftment was benchmarked against SCD donor and G-CSF-wild type mobilized CD34+ donor comparator datasets. Whole-genome sequencing was aligned and annotated to the hg38 reference genome.  

Results: SCD155 yielded 61.3-100 x106 CD34+ cells, representing 0.78-2.5% of the total PBMCs collected, with CD34+ purity varying between 98.5-99.9%. Benchmarking against 166 other SCD CD34+ isolations showed markedly elevated CD34+/PBMC in SCD155, with median CD34+/PBMC of 1.83% compared with 0.20% among other SCD isolations. SCD155 CD34+ cells demonstrated expected expansion and differentiation behavior in two-phase erythroid culture comparable to other SCD CD34+ cultures. F-cell and HbF readouts were comparable to other donors, supporting normal erythroid output and maturation. SCD155 CD34+ cells demonstrated robust engraftment, with hCD45+ chimerism ranging from 68.4-86.2%, across four NBSGW mice at 16-18 weeks post-transplant. This was higher than the comparator SCD2115, which showed median hCD45+ chimerism of 31.3% across eleven evaluable mice, compared with 84.0% for ALLO-0155 mice (Mann–Whitney U test, p=0.0015). SCD155 engraftment also approached the range observed in G-CSF-wild-type mobilized CD34+ donor, which showed hCD45+ chimerism of 82.5–98.0% across 15 mice. WGS analysis identified donor variants in published blood CD34+ GWAS/fine-mapping loci, including heterozygosity at the fine-mapped ENO1/RERE regulatory variant rs10864368 T/C, homozygosity for the CXCR4-associated variant rs309137 C/C, and heterozygosity for rs10193623 A/T 

Discussion: SCD155 represents an unusual SCD donor with repeated high-yield recovery of functionally competent CD34+ HSPCs from RCE-associated collections. Expected erythroid culture behavior, qualitative F-cell/HbF readouts, and robust in vivo engraftment in NBSGW mice demonstrate that the increased CD34+ recovery reflects a functional long-term HSPC product. WGS identified donor variants in ENO1/RERE and CXCR4 regulatory loci linked to blood CD34+ levels. SCD155 is heterozygous T/C at rs10864368, carrying one copy of the C allele at a GATA2-regulated ENO1/RERE element previously linked to higher ENO1/RERE expression and blood CD34+ levels. ENO1 functions in glycolysis and ENO1-linked enolase activity is pharmacologically targetable through inhibitor strategies (Lin et al., 2020) but inhibitor data from cancer models suggest ENO1 inhibition would reduce rather than increase stemness (Yang et al., 2020). Thus, this finding points to ENO1/RERE-linked metabolic regulation as a candidate pathway for preserved CD34+ recovery, rather than ENO1 inhibition as a mobilization strategy. Future work will compare ENO1/RERE expression, pathway activity, and regulatory variant burden across high- and low-yield SCD donors to define mechanisms of enhanced CD34+ mobilization and recovery.

Neha H. Suresh: No relevant conflicts of interest to declare.